![]() Therefore, early recognition and institution of appropriate antifungal agents is key to improve outcomes 8.Īs of 30 th September, 2021, Uganda has recorded over 123,500 cases of COVID-19 with over 3,150 of these patients dying from the disease 1. In published case series, CAPA has been reported to have a very high mortality rate in excess of 50% 7 – 9. Recently, fungal pathogens notably Candida, Histoplasma, Cryptococcus and Aspergillus species co-infections have been reported in patients with COVID-19 associated with a particularly poor outcomes 5, 6.ĬOVID-19 associated pulmonary aspergillosis (CAPA), is frequently observed in patients with moderate to severe COVID-19 disease, especially those on immunosuppressive therapy, underlying lung disease and those requiring invasive mechanical ventilation or extracorporeal membranous oxygenation 7, 8. Moreover, microbial co-infection occurs very early in patients with COVID-19 3.Īspergillus species are ubiquitous environmental molds that cause a spectrum of clinical pulmonary syndromes ranging from allergic, invasive and chronic disease with varying severity and clinical outcomes depending on the immune status of the host and the virulence of the etiologic Aspergillus species 4. A number of studies have documented SARS-CoV-2 co-infection with other pathogens. ![]() Experience from previous influenza pandemics have shown that microbial co-infection increases the risk of disease severity in humans infected with viral infections 2. As of 30 th September, 2021, over 234 million had contracted the disease, resulting to over 4.8 million deaths, worldwide 1. ![]() The coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected millions of individuals since December 2019, resulting in significant morbidity and mortality globally 1.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |